GLP1R and skin cancer: Our study revealed no significant differences in the hazard of negative control outcomes between the tirzepatide and GLP-1 RA groups for hernia, traumatic intracranial injury, sensorineural hearing loss, lumbar radiculopathy, and skin cancer.